I have an old deep vein thrombosis (DVT) and am on apixaban (Eliquis); a repeat Doppler ultrasound shows chronic DVT unchanged. Should I continue the same dose of apixaban?

Continue Apixaban, But Consider Dose Reduction to 2.5 mg Twice Daily

For chronic DVT on extended anticoagulation, you should continue apixaban but transition to the reduced dose of 2.5 mg twice daily rather than maintaining the full treatment dose of 5 mg twice daily. The unchanged Doppler findings confirm this is now chronic/stable disease requiring extended-phase (secondary prevention) rather than acute treatment-phase anticoagulation.

Rationale for Continuing Anticoagulation

Your patient has an unprovoked DVT (or one provoked by persistent risk factors), which mandates extended-phase anticoagulation according to CHEST guidelines 1. The guideline strongly recommends offering extended-phase anticoagulation with a DOAC for unprovoked VTE, as the risk of recurrence remains elevated even after completing initial treatment. Extended anticoagulation has no predefined stop date and should be reassessed at least annually 1.

Why Dose Reduction is Appropriate

After completing at least 6 months of full-dose anticoagulation, guidelines suggest using reduced-dose apixaban (2.5 mg twice daily) over full-dose (5 mg twice daily) for extended therapy 1. This recommendation is based on:

• Reduced bleeding risk: The reduced dose significantly decreases clinically relevant bleeding without compromising efficacy 2, 3
• Maintained efficacy: Recent high-quality evidence shows reduced-dose apixaban (2.5 mg BID) is noninferior to full-dose for preventing recurrent VTE 3
• FDA approval: The drug label specifically indicates 2.5 mg twice daily for "reduction in the risk of recurrence of DVT and PE" after at least 6 months of treatment 4

Clinical Decision Algorithm

Step 1: Confirm duration of current therapy

• If patient has been on apixaban for ≥6 months → proceed to dose reduction
• If <6 months → continue current dose until 6-month mark is reached

Step 2: Assess bleeding risk

• Low-moderate bleeding risk → transition to apixaban 2.5 mg twice daily
• High bleeding risk (active bleeding, recent major bleed, severe thrombocytopenia) → consider stopping anticoagulation or using aspirin as inferior alternative

Step 3: Verify this is truly unprovoked VTE

• No major transient risk factor (surgery >30 min, hospitalization ≥3 days, major trauma) within 3 months before DVT 1
• No minor transient risk factor (surgery <30 min, estrogen therapy, pregnancy, brief immobility) within 2 months before DVT 1
• If provoked by major transient factor → stop anticoagulation 1
• If provoked by minor transient factor → generally stop, though this is a weaker recommendation 1

Step 4: Implement dose reduction

• Switch from current dose to apixaban 2.5 mg twice daily
• No bridging or overlap needed—simply start the new dose at the next scheduled administration time 4

Supporting Evidence

The most recent and highest-quality evidence comes from the 2025 API-CAT trial 2, which demonstrated that in 1,766 patients with cancer-associated VTE, reduced-dose apixaban (2.5 mg BID) after 6 months was:

• Noninferior for preventing recurrent VTE (2.1% vs 2.8%, subhazard ratio 0.76)
• Superior for reducing clinically relevant bleeding (12.1% vs 15.6%, subhazard ratio 0.75, P=0.03)

Similarly, the 2025 HI-PRO trial 3 in provoked VTE with enduring risk factors showed reduced-dose apixaban dramatically reduced recurrent VTE compared to placebo (1.3% vs 10.0%, HR 0.13, P<0.001) with minimal bleeding risk.

Important Caveats

• Annual reassessment is mandatory: Patient preference, bleeding risk, and health status changes should trigger reevaluation of continued anticoagulation 1
• Chronic DVT on imaging is expected: The presence of chronic changes on repeat Doppler does not indicate treatment failure—it reflects post-thrombotic remodeling. What matters is preventing new/recurrent thrombosis, not resolving old clot
• Do not use D-dimer to guide stopping: A 2022 study 5 showed that D-dimer-guided discontinuation led to unacceptably high recurrence rates (7.3% vs 1.1% with continued apixaban), so do not stop based on D-dimer results
• Extended therapy duration: Studies monitored patients for 2-4 years, but the risk-benefit beyond this timeframe is uncertain 1

The reduced dose (2.5 mg BID) provides optimal balance between preventing life-threatening recurrent VTE and minimizing bleeding complications for long-term secondary prevention.